Morgan Stanley Krystal Biotech, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Morgan Stanley holds 275,804 shares of KRYS stock, worth $43.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

275,804

Previous 318,327 13.36%

Holding current value

$43.9 Million

Previous $58.5 Million 14.2%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $7.43 Million - $9.09 Million	-42,523 Reduced 13.36%	275,804 $50.2 Million
Q2 2024 Oct 17, 2024	BUY	$153.12 - $183.64 $15.2 Million - $18.3 Million	99,498 Added 45.47%	318,327 $58.5 Million
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $15.2 Million - $18.3 Million	99,498 Added 45.47%	318,327 $58.5 Million
Q1 2024 Oct 17, 2024	SELL	$108.01 - $179.35 $10.7 Million - $17.8 Million	-99,498 Reduced 31.26%	218,829 $38.9 Million
Q1 2024 Aug 16, 2024	SELL	$108.01 - $179.35 $10.9 Million - $18.1 Million	-100,892 Reduced 31.56%	218,829 $38.9 Million
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $10.9 Million - $18.1 Million	-100,892 Reduced 31.56%	218,829 $38.9 Million
Q4 2023 Aug 16, 2024	BUY	$96.0 - $128.29 $133,824 - $178,836	1,394 Added 0.44%	319,721 $39.7 Million
Q4 2023 Feb 13, 2024	BUY	$96.0 - $128.29 $2.99 Million - $4 Million	31,169 Added 10.8%	319,721 $39.7 Million
Q3 2023 Nov 15, 2023	BUY	$108.51 - $130.22 $1.49 Million - $1.79 Million	13,725 Added 4.99%	288,552 $33.5 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $11.6 Million - $19.3 Million	148,002 Added 116.7%	274,827 $32.3 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $4.4 Million - $5.12 Million	60,774 Added 92.01%	126,825 $10.2 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $1.18 Million - $1.5 Million	18,738 Added 39.6%	66,051 $5.23 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $2.08 Million - $2.64 Million	-32,041 Reduced 40.38%	47,313 $3.3 Million
Q2 2022 Oct 27, 2022	BUY	$48.93 - $73.47 $360,809 - $541,767	7,374 Added 10.24%	79,354 $5.21 Million
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $360,809 - $541,767	7,374 Added 10.24%	79,354 $5.21 Million
Q1 2022 Oct 27, 2022	SELL	$51.99 - $72.11 $383,374 - $531,739	-7,374 Reduced 9.29%	71,980 $4.79 Million
Q1 2022 May 13, 2022	SELL	$51.99 - $72.11 $2.03 Million - $2.81 Million	-39,018 Reduced 35.15%	71,980 $4.79 Million
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $3.1 Million - $6.86 Million	77,764 Added 233.99%	110,998 $7.76 Million
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $1.73 Million - $2.39 Million	33,234 New	33,234 $1.74 Million

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.3M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.09B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account